A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
NCT07332481
This study is recruiting at 12 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic disease. Study details include: Study Duration: Up to 35 weeks. Treatment Duration: 24 weeks. Visit Frequency: every 4 weeks, with the exception of the Week 2 televisit. Study Intervention Name: Enpatoran, Placebo. Intervention Form: Film-coated tablet.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Systemic Lupus Erythematosus (SLE)
- Cutaneous Lupus Erythematosus (CLE)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- EMD Serono Research & Development Institute, Inc.
- Last updated on ClinicalTrials.gov
- October 6, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- Dermatology Research Associates - 300204025 · Los Angeles, CA
- Cohen Medical Centers · Thousand Oaks, CA
Florida · 5
- GNP Research at Mark Jaffe, MD · Cooper City, FL
- Advance Medical Research Center · Miami, FL
- Diverse Clinical Research LLC · Miami, FL
- D&H National Research Centers, Inc. · Tamarac, FL
- Clinical Research of West Florida, Inc. · Tampa, FL
Georgia · 1
- Emory University School of Medicine · Atlanta, GA
Michigan · 1
- Revival Research Institute, LLC · Troy, MI
Texas · 3
- Allen Arthritis · Allen, TX
- Arthritis and Rheumatology Research Institute PLLC · Allen, TX
- Arthritis Care of Texas · Corpus Christi, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.